Biotechnology and Competitive Advantage: Europe’s Firms and the US Challenge

Investigates why Europe has fallen behind the US in applying biotechnology when the scientific capabilities of the two entities are about the same. Examines such issues as biotechnology policy in Europe as a whole and in individual countries; risk regulation and how industries, regulators, and non-government organizations manage it; the formation and roles of firms and their relative capabilities; gene therapy; and the impact on Europe of multinationals from there doing research overseas. Advocates integrating research and development in the two areas. Annotation c. by Book News, Inc., Portland, Or.